pT1a papillary thyroid carcinomas in pediatric patients

作者
T. Lai,Mya Bojarsky,Julia Baran,Amber Isaza,Lindsay Sisko,Stephanie Gonzales,Brianna Spatz,Tricia Bhatti,Lea F. Surrey,Zubair Baloch,N. Scott Adzick,Ken Kazahaya,Sogol Mostoufi‐Moab,Andrew J. Bauer
出处
期刊:European thyroid journal [S. Karger AG]
卷期号:14 (5)
标识
DOI:10.1530/etj-25-0119
摘要

Background Observational studies in adults suggest that incidental PTC (iPTC) and non-incidental PTC (niPTC) are distinct entities. We examine the incidence of iPTC in pediatric patients undergoing thyroidectomy for benign conditions and compare clinical and histopathologic findings, and outcomes, of iPTC with those of niPTC. Methods A retrospective chart review was conducted at the Children’s Hospital of Philadelphia between August 2010 and February 2023 to identify pediatric patients who underwent thyroidectomy and were diagnosed with pT1a PTC. Results iPTC was identified in 23 of 453 (5.1%) patients undergoing thyroidectomy for benign conditions. Within a cohort of 66 patients diagnosed with pT1a PTC, 23 (34.8%) were classified as iPTC and 43 (65.2%) were classified as niPTC. Compared to niPTC, iPTC had a significantly smaller median greatest dimension (iPTC: 3 mm, niPTC: 7 mm, P < 0.001), a lower rate of lymphatic invasion (iPTC: 0%, niPTC: 60.5%, P < 0.001), and AJCC N1 disease (iPTC: 0%, niPTC: 55.8%, P < 0.001). Most iPTC (22 out of 23 (95.7%)) were classified as ATA pediatric low-risk, while six out of 43 (14.0%) niPTC were categorized as intermediate/high-risk. Patients with iPTC and niPTC were followed for a median of 3.3 and 5.7 years, respectively. There was no evidence of persistent or recurrent disease in any patient with iPTC during this time frame. Conclusions iPTC may be found in 5.1% of pediatric patients undergoing thyroidectomy for benign conditions. Similar to adults, iPTC in pediatric patients appears to be indolent with a minimal risk for invasive features and a low risk for persistent or recurrent disease. In contrast to iPTC, niPTC exhibits the potential for invasive behavior and should be regarded as a distinct entity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zzzxiangyi完成签到,获得积分10
3秒前
3秒前
时尚溪流完成签到,获得积分10
4秒前
Owen应助dh采纳,获得10
4秒前
随机刷新的小白完成签到,获得积分10
5秒前
开心科研完成签到,获得积分10
6秒前
6秒前
邵初蓝完成签到,获得积分10
6秒前
伍六柒完成签到,获得积分10
6秒前
6秒前
青青草完成签到,获得积分10
7秒前
甜甜友容完成签到,获得积分10
8秒前
沉默的西牛完成签到,获得积分10
8秒前
小恐龙发布了新的文献求助10
8秒前
8秒前
yong完成签到 ,获得积分10
9秒前
漂亮天真完成签到,获得积分10
9秒前
高兴吐司完成签到,获得积分10
10秒前
流星逐月完成签到,获得积分10
10秒前
10秒前
研友_La17wL完成签到,获得积分10
11秒前
ssy发布了新的文献求助10
11秒前
柳贯一应助开心科研采纳,获得10
11秒前
可爱的梦柏完成签到,获得积分10
12秒前
稳重小刺猬应助江浔卿采纳,获得10
12秒前
crz完成签到,获得积分10
12秒前
12秒前
小罗完成签到,获得积分10
13秒前
Yw_M完成签到,获得积分10
13秒前
扎西娃子完成签到,获得积分10
13秒前
闪闪发光的队长完成签到,获得积分10
14秒前
西子完成签到,获得积分10
14秒前
15秒前
外向的含羞草完成签到,获得积分10
15秒前
Tomin完成签到,获得积分0
15秒前
低级趣味完成签到,获得积分10
15秒前
尊敬依珊完成签到 ,获得积分10
15秒前
心灵美砖头完成签到,获得积分10
16秒前
LH完成签到,获得积分10
16秒前
CC完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
University Physics for the Life Sciences 500
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6951311
求助须知:如何正确求助?哪些是违规求助? 8635520
关于积分的说明 18310410
捐赠科研通 6393497
什么是DOI,文献DOI怎么找? 3082009
关于科研通互助平台的介绍 2127113
邀请新用户注册赠送积分活动 2058891